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Introduction: We performed a meta-analysis to investigate the risk of deep vein thrombosis (DVT) and/or
pulmonary embolisms (PEs) in patients with inflammatory arthritis, vasculitis and connective tissue diseases (CTDs)
(systemic lupus erythematosus (SLE), Sjögren’s syndrome, inflammatory myositis and systemic sclerosis (SSc)).
Methods: PubMed, Embase, the Cochrane databases and MEDLINE were searched to identify full-text
English-language publications about adult patients with rheumatologic inflammatory diseases and venous
thromboembolisms (VTEs). Data regarding rates of DVTs and PEs were extracted. Using random-effects models,
pooled estimates for VTEs in individual and pooled diseases were compared with matched populations where
possible. Studies were excluded if VTEs were described in the setting of pregnancy, postoperative outcomes or
solely antiphospholipid antibody syndrome.
Results: Most of the 5,206 studies were excluded because they did not state the rate or incidence of VTEs. In total,
25 studies remained for analysis. Ten studies that included rheumatoid arthritis comprised an aggregate of
5,273,942 patients and 891,530,181 controls with a cumulative VTE incidence of 2.18% (95% confidence interval (CI):
1.82% to 2.54%) and an odds ratio of 2.23 (95% CI: 2.02 to 2.47) compared to age- and sex-matched populations.
Ten studies comprised an aggregate of 54,697 SLE patients with a cumulative VTE incidence of 7.29% (95% CI:
5.82% to 8.75%). Four Sjögren’s syndrome studies comprising an aggregate of 25,100 patients demonstrated a
cumulative VTE incidence of 2.18% (95% CI: 0.79% to 3.57%). Four studies of inflammatory myositis comprising an
aggregate of 8,245 patients yielded a cumulative VTE incidence of 4.03% (95% CI: 2.38% to 5.67%). The SSc- and
antineutrophil cytoplasmic antibody vasculitis–related cumulative VTE rates (four studies each) were 3.13% and
7.97%, respectively.
Conclusions: The inflammatory rheumatologic diseases studied were all associated with high rates of VTEs—more
than three times higher than in the general population.Introduction
Venous thromboembolism (VTE) is a vascular phe-
nomenon that includes clinical entities such as deep vein
thrombosis (DVT) and pulmonary embolism (PE). These
venous coagulopathies usually occur in the setting of
Virchow’s triad, which describes conditions in which
thromboses develop as a consequence of stasis, endo-
thelial injury and innate hypercoagulability [1,2]. It is* Correspondence: janet.pope@sjhc.london.on.ca
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stated.increasingly becoming recognized that active inflamma-
tion is an important process that increases coagulability
and leads to thrombosis [3]. Active inflammation is a
prothrombotic state characterized by upregulation of
tumor necrosis factor α (TNF-α) and activation of endo-
thelial cells. It is thought that upregulation of TNF-α in-
creases tissue factor in the serum, which is a natural
procoagulant, while downregulating protein C, which is
a natural anticoagulant [3]. Also, activation of endothe-
lial cells promotes platelet activation, which is import-
ant for thrombus formation.
Rheumatologic conditions are often inflammatory by
nature. However, despite this mechanistic link betweenl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Lee and Pope Arthritis Research & Therapy 2014, 16:435 Page 2 of 8
http://arthritis-research.com/content/16/5/435rheumatologic diseases and VTEs, these highly inflam-
matory conditions may be under-recognized as risk fac-
tors for hypercoagulability. The only exception is the
well-known association between antiphospholipid anti-
bodies in systemic lupus erythematosus (SLE) and both
venous and arterial thromboses. There are several case
reports, retrospective cohort studies and prospective ob-
servational analyses highlighting the increased risk of
VTE in patients with rheumatologic diseases [4-9]. Most
of the data in the literature reveal this concern in pa-
tients with rheumatoid arthritis (RA) and SLE, and the
SLE studies are focused mostly on increased risks associ-
ated with positive antiphospholipid status rather than on
the innate hypercoagulability nature of this inflammatory
disease [8,10]. VTEs seem to be linked to disease activity
and/or inflammation in many of the inflammatory rheu-
matologic diseases.
Patients who develop VTEs have high rates of morbid-
ity and mortality [2]. The incidence of first-time VTE in
the United States is about 1 in 1,000 person-years [1].
Therefore, it is important to understand the excess mag-
nitude of this issue in patients with inflammatory rheu-
matologic diseases. Ideally, the modifiable risk factors
would be known and altered and poor outcomes miti-
gated. To investigate these issues, we conducted a meta-
analysis of the risk of developing DVT and/or PE in
patients with inflammatory arthritis, vasculitis and con-
nective tissue diseases (CTDs) such as SLE, Sjögren’s
syndrome, inflammatory myositis and systemic sclerosis.
Methods
Search strategy
We performed a literature search of English-language
publications related to VTE, DVT and/or PE in patients
with inflammatory arthritis, vasculitis and CTDs such as
SLE, Sjögren’s syndrome, inflammatory myositis and sys-
temic sclerosis. We searched for articles in MEDLINE,
Embase, PubMed and the Cochrane databases from their
inception (1966, 1950, 1980 and 1991, respectively) to
June 2014 (Additional file 1). All studies that included
thrombosis in the setting of inflammatory rheumatologic
diseases were collected. Inclusion criteria included arti-
cles published in English with rates of VTE in adult pa-
tients with the aforementioned rheumatologic diseases.
Exclusion criteria included articles reporting VTE in the
setting of antiphospholipid antibodies, pregnancy-related
outcomes and postoperative outcomes. The details of
our search strategy are given in Additional file 1.
Description of studies
Both authors agreed on which studies were included and
excluded. Data from each study were extracted by one in-
vestigator (JJL). The following information was systematic-
ally extracted: first author, year of publication, countrywhere the study was done, total number of patients in-
cluded (cases and controls), total number of VTE events
observed in the inflammatory rheumatologic disease, total
number of control patient population where available and
total number of VTE events observed in the control co-
hort where available. Some studies included multiple
patient populations with various rheumatologic diseases.
Therefore, from those articles, data were extracted for
each disease and analyzed separately.
Quality assessment
Study quality was assessed by using the Strengthening
the Reporting of Observational Studies in Epidemiology
(STROBE) checklist for cohort, case–control and cross-
sectional studies. The STROBE checklist consists of 22
items; 18 items are common to all three study designs,
and 4 items (6a/6b, 12d, 14c and 15) are specific to cohort,
case–control and cross-sectional studies. The maximum
score varies based on the number of applicable items on
the checklist. Two items on the checklist (items 12e and
16c) pertain to statistical methods. Item 12e describes any
sensitivity analysis of the main results, and, for item 16c,
where relevant, the relative risk is translated into absolute
risk for a meaningful time period. Therefore, these items
were not relevant to all of the articles. One item applied
only to matched studies (item 6b) and another only to co-
hort studies (item 14c). The maximum attainable score is
32. The purpose of STROBE is not to give a quality score,
but to ensure clear presentation of reporting.
Statistical analysis
Forest plots of VTE rates were graphed separately from
the available articles. Estimates of VTEs by sample size
were examined to determine if larger samples had fewer
outlying estimates. Confidence intervals (CIs) at the 95%
level for study estimates were calculated using Wilson’s
scoring method [11]. Within-study variance was estimated
by using the formula Vari = pi*(1 − pi)/Ni [12], where pi is
the estimate of the true proportion of patients with the
condition for study i and Ni is the total sample size of
study i [12]. Study weights were calculated as the inverse
of the within-study variance. A random-effects meta-
analysis was used to pool study proportion estimates
while accounting for differences in study quality, study
population and study design [13]. The I2 statistic was
used to quantify the magnitude of between-study het-
erogeneity [14]. An I2 value represents the percentage of
total variation across studies due to true difference ra-
ther than to chance, with values of 0% to 30%, 31% to
50%, and >50% representing mild, moderate and notable
heterogeneity, respectively [14]. The τ2 value was the
square root of the between-study variance, and the P-value
was calculated with Cochrane’s Q test, the classic measure
of heterogeneity. Statistical analyses were performed using
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Vienna, Austria). Many of the studies included in the
meta-analysis did not report a control group; therefore,
relative risks and odds ratios could not be calculated for
the diseases described in those articles.
Results
Search results
In the search process, we identified 5,206 articles (Figure 1).
During the title review process, 1,007 articles were re-
moved as duplicate citations from different databases.
Next, during the abstract review process, 4,114 articles
were eliminated because they were irrelevant (that is, not
related to VTE). Subsequently, one new article, pending
publication and based on an abstract presented at the 2013
American College of Rheumatology meeting [15], was
included. The exclusion criteria were applied to the
remaining 85 unique articles, and 60 studies were ex-
cluded. Thus, the final review included 25 unique arti-
cles [4-9,15-33] (Table 1).
Studies included
Ultimately, 25 articles were subject to full review. Of the
25 articles, seven were from the United States [6,8,
16,17,19,29], five were from Canada [4,15,23-25], four
were from Taiwan [18,31-33], two were from the United
Kingdom [5,22], two were from Sweden [7,21], one was
from Mexico [20], one was from Spain [27], one was
from Denmark [26], one was from the Netherlands [28]Figure 1 Flowchart of the search strategy, selection process and num
American College of Rheumatology; CTD, Connective tissue disease; DVT, D
arthritis; SSc, Systemic sclerosis; SLE, Systemic lupus erythematosus; VTE, Veand one was from France [30]. Several studies included
multiple rheumatologic diseases [15-17], and data were
extracted according to disease. The included articles are
summarized in Table 1 according to disease, along with
descriptive statistics on the cumulative incidence of
VTEs. The maximum attainable score was 32 for the
STROBE checklist, and the mean score for 24 articles
was 26.5 (range: 24 to 30), not including the one ab-
stract from the 2013 American College of Rheumatol-
ogy meeting [15].
Analyses
Of the 25 studies, 10 included patients with RA. In the
aggregate, these studies identified a total of 5,273,942
patients and 891,530,181 controls with a VTE cumula-
tive incidence of 2.18% (95% CI: 1.82% to 2.54%). The
odds ratio of RA patients’ developing DVT and/or PE
was 2.23 (95% CI: 2.02 to 2.47) compared to age-, sex- and
other comorbidity-matched populations such as diabetes
mellitus, peripheral vascular disease and/or coronary ar-
tery disease, and malignancy. In 10 studies that included
patients with SLE, researchers observed an aggregate of
54,697 patients with a VTE cumulative incidence of 7.29%
(95% CI: 5.82% to 8.75%). Four Sjögren’s syndrome studies
with an aggregate of 25,100 subjects demonstrated a VTE
cumulative incidence of 2.18% (95% CI: 0.79% to 3.57%).
Four studies of inflammatory myositis (dermatomyositis
and/or polymyositis) (N =8,245) resulted in a VTE cumu-
lative incidence of 4.03% (95% CI: 2.38% to 5.67%). Fourber of articles identified, excluded and included for analysis. ACR,
eep vein thrombosis; PE, Pulmonary embolism; RA, Rheumatoid
nous thromboembolism.
Table 1 Characteristics of studies included with descriptive statistics on rates of venous thromboembolisma









Choi et al. [5] 2013 The Health Improvement Network UK 9,589 192 95,776 870
Bacani et al. [6] 2012 Olmsted County, Minnesota USA 464 19 464 7
Holmqvist et al. [7] 2012 National Patient Register Sweden 39,372 838 173,417 1,866
Matta et al. [16] 2009 National Hospital Discharge Survey USA 4,818,000 110,000 891,055,000 10,227,000
Liang et al. [17] 2006 Olmsted County, Minnesota USA 609 38 N/A N/A
Chung et al. [18] 2013 Taiwan National Health Insurance
Research Database
Taiwan 29,238 278 116,952 394
Kim et al. [19] 2013 US insurance claims USA 22,143 265 88,572 448
Romero-Díaz et al. [20] 2009 Instituto Nacional de Ciencias Médicas y
Nutrición Salvador Zubirán
Mexico 156 3 N/A N/A
Zöller et al. [21] 2012 MigMed2 database Sweden 86,366 2,500 N/A N/A
Ramagopalan et al. [22] 2011 Oxford Record Linkage Study UK 268,005 6,825 N/A N/A
Systemic lupus erythematosus
Aviña-Zubieta et al. [4] 2012 University of British Columbia Canada 5,031 265 50,310 533
Calvo-Alén et al. [8] 2005 LUMINA Study Group USA 570 51 N/A N/A
Kaiser et al. [9] 2009 UCSF Lupus Genetics Project USA 1,930 426 N/A N/A
Romero-Díaz et al. [20] 2009 Instituto Nacional de Ciencias Médicas y
Nutrición Salvador Zubirán
Mexico 241 25 N/A N/A
Zöller et al. [21] 2012 MigMed2 database Sweden 9,147 276 N/A N/A
Ramagopalan et al. [22] 2011 Oxford Record Linkage Study UK 23,544 636 N/A N/A
Sarabi et al. [23] 2005 University of Toronto Lupus Database Canada 544 30 N/A N/A
Chang et al. [24] 2006 McGill University Health Centre Lupus
Clinic Registry
Canada 426 40 N/A N/A
Gladman and Urowitz [25] 1980 Lupus Clinic at the Wellesley Hospital Canada 180 17 N/A N/A
Chung et al. [32] 2014 Taiwan National Health Insurance
Research Database
Taiwan 13,084 228 52,336 61
Sjögren’s syndrome
Zöller et al. [21] 2012 MigMed2 database Sweden 3,410 100 N/A N/A
Ramagopalan et al. [22] 2011 Oxford Record Linkage Study UK 12,680 305 N/A N/A
Haga et al. [26] 2008 Haukeland University Hospital Norway 90 4 N/A N/A
Chung et al. [31] 2014 Taiwan National Health Insurance
Research Database
Taiwan 8,920 59 35,680 98
Inflammatory myositis
Romero-Díaz et al. [20] 2009 Instituto Nacional de Ciencias Médicas y
Nutrición Salvador Zubirán
Mexico 24 2 N/A N/A
Zöller et al. [21] 2012 MigMed2 database Sweden 2,122 92 N/A N/A
Ramagopalan et al. [22] 2011 Oxford Record Linkage Study UK 6,002 167 N/A N/A
Selva-O’Callaghan et al. [27] 2011 Vall d’Hebron General Hospital Spain 97 9 N/A N/A
Systemic sclerosis
Zöller et al. [21] 2012 MigMed2 database Sweden 9,323 370 N/A N/A
Ramagopalan et al. [22] 2011 Oxford Record Linkage Study UK 11,643 244 N/A N/A
Aviña-Zubieta et al. [15] 2013 University of British Columbia Canada 1,284 73 12840 197
Chung et al. [33] 2014 Taiwan National Health Insurance
Research Database
Taiwan 1,895 22 7,580 12
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ANCA-associated vasculitis
Zöller et al. [21] 2012 MigMed2 database Sweden 15,085 878 N/A N/A
Stassen et al. [28] 2008 University of Groningen Netherlands 198 23 N/A N/A
Merkel et al. [29] 2005 The Wegener’s Granulomatosis
Etanercept Trial Research Group
USA 167 16 N/A N/A
Allenbach et al. [30] 2009 French Vasculitis Study Group Cohort France 845 67 N/A N/A
aANCA, Antineutrophil cytoplasmic antibody; DVT, Deep vein thrombosis; N/A, Not available; RA, Rheumatoid arthritis; VTE, Venous thromboembolism.
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associated vasculitis (N =16,295) resulted in a VTE cu-
mulative incidence of 7.97% (95% CI: 5.67% to 10.28%).
Four studies analyzed VTE rates for systemic sclerosis
(N =24,145), which resulted in a VTE cumulative inci-
dence of 3.13% (95% CI: 1.73% to 4.52%). There were
no independent data available for other inflammatory
arthritides such as spondyloarthropathies. Overall, all
inflammatory rheumatologic diseases were associated
with high rates of VTEs (Figure 2).Figure 2 Forrest Plots of VTE rates and odds ratios in patients with rh
compared to matched control population presented as Odds Ratio. (b) Cu
compared to matched control population presented as Odds Ratio.Discussion
Patients with inflammatory rheumatologic diseases are
at increased risk of developing VTEs. To our knowledge,
our present meta-analysis is the first to show this in-
creased inherent risk in patients across all inflammatory
rheumatologic diseases. This increased risk was seen in
studies of hospitalized and nonhospitalized patients. Spe-
cifically, patients with RA, SLE, inflammatory myositis,
Sjögren’s syndrome, ANCA-associated vasculitis and sys-
temic sclerosis appear to have this increased risk. Thereeumatologic diseases. (a) Cumulative Incidence of VTEs in RA
mulative Incidence of VTEs in patients with RA, SLE, Scleroderma
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on risks for other inflammatory conditions.
Certainly, patients with various rheumatologic illnesses
may be at increased risk of developing VTEs for several
different reasons. Patients with inflammatory joint dis-
eases are more likely to be immobile because of pain, es-
pecially during times of active joint inflammation. Also,
these patients are more likely to undergo surgeries such
as joint arthroplasty procedures. We attempted to account
for these confounders in this meta-analysis by excluding
VTE rates reported in the perioperative setting. The inher-
ent hypercoagulable nature of inflammatory autoimmune
diseases is often overlooked [1,2]. This is despite recent
evidence which suggests that active inflammation is a
strong driving force that leads to local and systemic imbal-
ances in the coagulation system [3].
The data presented in our present study are clinically
significant when considering the morbidity and mortality
associated with VTEs [1,2]. In a recently published epi-
demiological study by Tagalakis et al. [2], the 1-year sur-
vival rate of unprovoked VTEs was estimated to be only
93%. For patients who developed a VTE secondary to a
major risk factor such as recent surgery or hospitalization,
the 1-year survival rate was only 84%. If the patient sur-
vives a VTE episode, the subsequent cost of rehabilitation
and long-term anticoagulation is great. Also, by recogniz-
ing active inflammation as a risk factor for VTEs, the
duration of anticoagulation may be adjusted once an event
has occurred. This may be an area of future research in
both rheumatology and hematology.
Recognizing a risk factor is only part of the battle. The
natural follow-up to the results reported here is to deter-
mine factors important in prevention and when, if at all,
it is appropriate to use prophylaxis. There are limited
and scant data in the literature regarding this issue. Most
of the literature regarding prophylaxis against VTEs in
rheumatology patients focuses on antiphospholipid anti-
body status. Specifically, hydroxychloroquine has shown
promise in reducing the incidence of VTEs in patients
with SLE [34,35]. Aspirin also seems to be beneficial in
the setting of antiphospholipid antibodies, particularly
during pregnancy [36]. However, there are no studies in
the current literature in which the benefit of aspirin in
rheumatologic patients without antiphospholipids in the
serum has been assessed.
We believe that the increased VTE risk is associated
with the activity of the inflammatory diseases rather than
with the treatments used for controlling the disease. There
are two major reasons for this hypothesis. First, some of
these studies show that the risk of VTE is highest in the
first year of disease, with a significant drop-off in subse-
quent years. Some postulate that this is because the dis-
ease is most active in the first year, with improvement
occurring once inflammation is controlled by medications.Second, studies of vasculitis, such as ANCA-associated
vasculitides and giant cell arteritis show that the risk of
thrombosis is lower when the disease is treated with glu-
cocorticoids and disease-modifying agents. Therefore, we
believe that the risk of thrombosis is associated with the
disease. However, further studies are required to confirm
this hypothesis.
To our knowledge, this meta-analysis is the first com-
prehensive study to recognize the hypercoagulability risk
in patients with many inflammatory rheumatologic con-
ditions. Notable limitations of this meta-analysis include
possible publication bias. Due to underrecognition of
this issue in the published literature and in practice,
negative studies may not have been available for inclu-
sion. However, under the same principle, rates of VTE in
the published literature may underestimate true rates.
Clinical signs of VTEs, especially DVTs, are often
subtle. Patient-reported symptoms may be vague and
may even be misattributed to their rheumatologic dis-
ease. Another potential limitation of this meta-analysis
involves lack of prospective data that include disease
activity, other comorbidities and confounders. Particu-
larly in studies without control comparators, it may be
difficult to isolate patients’ rheumatologic diseases as
the sole cause for VTEs.
With regard to the increased risk in patients with SLE-
and ANCA-associated vasculitis, we also recognize that
their risk is substantially higher compared to the other
disease populations. For ANCA-associated vasculitides,
we felt that the risk was attributable to a combination of
(1) direct vessel injury from inflammation (vasculitis),
(2) greater local edema and vascular narrowing second-
ary to vascular inflammation and remodeling and
(3) overall inflammatory state, as in all other inflamma-
tory diseases. Of course, further investigations are re-
quired to prove this theory. With regard to the increased
risk in SLE, again it is likely a multifactorial issue, in-
cluding renal involvement (such as nephrotic syndrome,
which can increase hypercoagulability by an imbalance
in excreting antithrombotic factors), an increased preva-
lence of antiphospholipid antibodies and an overall in-
flammatory state, as in all other inflammatory diseases
leading to endothelial dysfunction and via other mecha-
nisms. Specifically with regard to antiphospholipid
antibody status, we tried to mitigate this confounder as
much as possible by excluding studies that directly tested
for hypercoagulability in the setting of known antipho-
spholipids in the serum. However, we recognize that the
studies included did not specifically test for or exclude
antiphospholipid status, so it is probable that at least some
of the increased VTE risk in SLE patients is due to anti-
phospholipid antibodies. The prevalence of antiphospholi-
pid syndrome in SLE patients can vary by cohort, so part
of the usual lupus cohort studied would have one-fourth
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lupus. In general, none of the included studies reported
disease activity in relation to the VTE events, so we were
unable to perform subanalyses in this regard.
In our present meta-analysis, we pooled the studies
using a random-effects model. However, high heterogen-
eity was still observed, owing to the wide differences in
patient populations in each cohort. These differences
included ethnicity, age, duration of disease, activity of
disease, setting of VTE (that is, inpatient vs. outpatient),
environmental factors and other unknown variables. We
tried to minimize the variance by including large studies
with clearly defined patient characteristics. Still, there
were a limited number of studies from which data were
pooled. However, for all inflammatory rheumatic dis-
eases for which data were extracted, the rate of VTEs
was higher than expected, with a pooled increased odds
ratio of 3.4.
Conclusion
In this study, we quantified the elevated risk of venous
thromboembolic events in patients across the included
inflammatory rheumatologic diseases. Although we pro-
vide strong evidence for this elevated baseline risk in the
rheumatology patient population, identifying high-risk
patients within each disease and reducing the risk by
treatment of disease activity or antiplatelet prophylaxis
cannot be determined on the basis of our meta-analysis.
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